Tags

Type your tag names separated by a space and hit enter

The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction.
Neurourol Urodyn. 2009; 28(8):964-8.NU

Abstract

AIM

The aim of this study was to investigate the effect of PTNS after 12 weeks, on the urodynamic findings in the Multiple Sclerosis (MS) patients with neurogenic detrusor overactivity (NDO).

METHODS

A total of 19 MS patients with NDO were enrolled in the study. Urodynamic studies before and after 12 weeks PTNS were performed. PTNS was applied unilaterally from the medial malleolus and posterior to the edge of the tibia by using charge-compensated 200 micros pulses with a pulse rate of 20 Hz, weekly, during 3 months. The effects of PTNS on urodynamic variables were compared of baseline and after PTNS data in MS patients.

RESULTS

Mean volume at the first involuntary detrusor contraction (1st IDCV) on standard cystometry was 124.2+/-37.6 ml, while it was 217.5+/-66.4 mL after PTNS. Mean maximum cystometric capacity (MCC) on standard cystometry was 199.7+/-29.3 mL, while it was 266.8+/-36.9 mL after stimulation. The improvements in the 1st IDCV and MCC were statistically significant after stimulation. Mean P(detmax) at first involuntary detrusor contraction, maximal detrusor pressure at maximum cystometric capacity, detrusor pressure at maximal flow (P(detQmax)) and maximal flow rate (Q(max)) were statistically significant after PTNS for 12 weeks.

CONCLUSIONS

These results have demonstrated that PTNS is effective to suppress NDO in MS patients after PTNS. Although long-term efficacy of PTNS is known, the findings showed prominent improvements on the clinical and urodynamic outcome, we think that the use of PTNS for DO in MS patients will be promising in clinical practice in the future.

Links

Publisher Full Text

Authors+Show Affiliations

Kabay S
Faculty of Medicine, Department of Urology, Dumlupinar University, Kutahya, Turkey. skabay@yahoo.com
Kabay SC
No affiliation info available
Yucel M
No affiliation info available
Ozden H
No affiliation info available
Yilmaz Z
No affiliation info available
Aras O
No affiliation info available
Aras B
No affiliation info available

MeSH

AdultFemaleHumansMaleMiddle AgedMultiple SclerosisTibial NerveTime FactorsTranscutaneous Electric Nerve StimulationUrinary Bladder, NeurogenicUrodynamics

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19373898

Citation

Kabay, Sahin, et al. "The Clinical and Urodynamic Results of a 3-month Percutaneous Posterior Tibial Nerve Stimulation Treatment in Patients With Multiple Sclerosis-related Neurogenic Bladder Dysfunction." Neurourology and Urodynamics, vol. 28, no. 8, 2009, pp. 964-8.
Kabay S, Kabay SC, Yucel M, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009;28(8):964-8.
Kabay, S., Kabay, S. C., Yucel, M., Ozden, H., Yilmaz, Z., Aras, O., & Aras, B. (2009). The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourology and Urodynamics, 28(8), 964-8. https://doi.org/10.1002/nau.20733
Kabay S, et al. The Clinical and Urodynamic Results of a 3-month Percutaneous Posterior Tibial Nerve Stimulation Treatment in Patients With Multiple Sclerosis-related Neurogenic Bladder Dysfunction. Neurourol Urodyn. 2009;28(8):964-8. PubMed PMID: 19373898.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. AU - Kabay,Sahin, AU - Kabay,Sibel Canbaz, AU - Yucel,Mehmet, AU - Ozden,Hilmi, AU - Yilmaz,Zahide, AU - Aras,Ozgen, AU - Aras,Bahar, PY - 2009/4/18/entrez PY - 2009/4/18/pubmed PY - 2010/3/4/medline SP - 964 EP - 8 JF - Neurourology and urodynamics JO - Neurourol Urodyn VL - 28 IS - 8 N2 - AIM: The aim of this study was to investigate the effect of PTNS after 12 weeks, on the urodynamic findings in the Multiple Sclerosis (MS) patients with neurogenic detrusor overactivity (NDO). METHODS: A total of 19 MS patients with NDO were enrolled in the study. Urodynamic studies before and after 12 weeks PTNS were performed. PTNS was applied unilaterally from the medial malleolus and posterior to the edge of the tibia by using charge-compensated 200 micros pulses with a pulse rate of 20 Hz, weekly, during 3 months. The effects of PTNS on urodynamic variables were compared of baseline and after PTNS data in MS patients. RESULTS: Mean volume at the first involuntary detrusor contraction (1st IDCV) on standard cystometry was 124.2+/-37.6 ml, while it was 217.5+/-66.4 mL after PTNS. Mean maximum cystometric capacity (MCC) on standard cystometry was 199.7+/-29.3 mL, while it was 266.8+/-36.9 mL after stimulation. The improvements in the 1st IDCV and MCC were statistically significant after stimulation. Mean P(detmax) at first involuntary detrusor contraction, maximal detrusor pressure at maximum cystometric capacity, detrusor pressure at maximal flow (P(detQmax)) and maximal flow rate (Q(max)) were statistically significant after PTNS for 12 weeks. CONCLUSIONS: These results have demonstrated that PTNS is effective to suppress NDO in MS patients after PTNS. Although long-term efficacy of PTNS is known, the findings showed prominent improvements on the clinical and urodynamic outcome, we think that the use of PTNS for DO in MS patients will be promising in clinical practice in the future. SN - 1520-6777 UR - https://www.unboundmedicine.com/medline/citation/19373898/The_clinical_and_urodynamic_results_of_a_3_month_percutaneous_posterior_tibial_nerve_stimulation_treatment_in_patients_with_multiple_sclerosis_related_neurogenic_bladder_dysfunction_ L2 - https://doi.org/10.1002/nau.20733 DB - PRIME DP - Unbound Medicine ER -